Hypothalamic regulation of obesity: Revealing the therapeutic potential of a novel anti-obesity peptide
Vascular Pharmacology · 2025-12 · 161 · 107553
DOI: 10.1016/j.vph.2025.107553 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vascular Pharmacology, 2025-12. Verfasst von Yi Ning Choo und 2 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacology, Department of Biomedical Sciences, Sir Jeffrey Cheah Sunway Medical School, Faculty of Medical and Life Sciences, Sunway Un…. Hauptthemen laut MEDLINE: Obesity, Anti-Obesity Agents, Hypothalamus, Energy Metabolism. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 134 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Obesity is a chronic, complex condition defined by excessive fat buildup due to an imbalance between caloric consumption and energy expenditure. The significant global rise in prevalence of obesity is associated with numerous comorbidities, such as cardiovascular disease, type 2 diabetes, and non-alcoholic fatty liver disease. Conventional management approaches, including diet, exercise, pharmacotherapy, and bariatric surgery, may demonstrate restricted long-term effectiveness owing to inadequate adherence and physiological adjustments. Recent advancements in neuroscience underscore the hypothalamus as a pivotal regulator of energy balance via essential nuclei, including the arcuate nucleus (ARC), paraventricular nucleus (PVN), lateral hypothalamic area (LHA), and ventromedial nucleus (VMN). This review examines the therapeutic potential of a new anti-obesity peptide that targets hypothalamic signalling pathways. Preclinical and clinical evidence endorses the utilization of glucagon-like peptide-1 receptor (GLP-1R) agonists and novel multi-receptor drugs such as AMG 133, which integrate GLP-1R activation with glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism. These therapies exhibit improved weight reduction and metabolic enhancement. Moreover, the integration of hypothalamic peptide therapy with lifestyle modifications or post-bariatric care provides synergistic advantages. Notwithstanding favorable results, peptide therapy encounters obstacles such as administration methods, sustained effectiveness, and expense. Overcoming these obstacles is crucial for the effective implementation of peptide-based treatments in sustained clinical obesity control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacology, Department of Biomedical Sciences, Sir Jeffrey Cheah Sunway Medical School, Faculty of Medical and Life Sciences, Sunway University, Malaysia.
- Jeffrey Cheah School of Medicine and Health Sciences, Monash University Malaysia, Bandar Sunway, Selangor Darul Ehsan, Malaysia. Electronic address: ram.ravi@monash.edu.
- Division of Pharmacology, Department of Biomedical Sciences, Sir Jeffrey Cheah Sunway Medical School, Faculty of Medical and Life Sciences, Sunway University, Malaysia. Electronic address: vetris@sunway.edu.my.
Zitieren
APA
Choo, Y. N., Narayanan, R., & Subramaniyan, V. (2025). Hypothalamic regulation of obesity: Revealing the therapeutic potential of a novel anti-obesity peptide. Vascular Pharmacology, 161, 107553. https://doi.org/10.1016/j.vph.2025.107553
Vancouver
Choo YN, Narayanan R, Subramaniyan V. Hypothalamic regulation of obesity: Revealing the therapeutic potential of a novel anti-obesity peptide. Vascular Pharmacology. 2025;161:107553. doi:10.1016/j.vph.2025.107553
BibTeX
@article{Choo2025,
author = {Choo, Yi Ning and Narayanan, Ram and Subramaniyan, Vetriselvan},
title = {Hypothalamic regulation of obesity: Revealing the therapeutic potential of a novel anti-obesity peptide},
journal = {Vascular Pharmacology},
year = {2025},
volume = {161},
pages = {107553},
doi = {10.1016/j.vph.2025.107553}
}
EUVIMED